MS Block et al. AACR 2022 Download the publication here
Category: dates
Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF
JB Marchand et al. AACR 2022 Abstract available on the AACR website – Download the poster
Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients
MS Block et al.AACR 2022Read the abstract here – Download the poster herePoster Presentation
Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050
Transgene to present new positive preliminary Phase I Clinical data
Availability of Transgene’s 2021 Universal Registration Document
Availability of Transgene’s universal registration document
Availability of Preparatory Documents for the Combined General Meeting of May 25, 2022
Availability of Preparatory documents
Transgene’s Board of Directors strengthens its governance and proposes the appointment of Dr. Alessandro Riva as Independent Chairman
Transgene’s board of directors strengthens its governance
Transgene confirms the potential of its two innovative platforms and expects significant clinical results in 2022
Transgene confirms the potential of its two innovative platforms
Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022
Transgene to present new positive preliminary Phase I data on TG4050
Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022
Transgene and BioInvent Announce Poster Presentation on BT-001